Literature DB >> 20878765

The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation.

Oscar Gomez1, Angel Arevalo-Martin, Daniel Garcia-Ovejero, Silvia Ortega-Gutierrez, Jose Antonio Cisneros, Guillermina Almazan, María Alejandra Sánchez-Rodriguez, Francisco Molina-Holgado, Eduardo Molina-Holgado.   

Abstract

Endocannabinoids have recently emerged as instructive cues in the developing central nervous system, and, based on the expression of their receptors, we identified oligodendrocytes as potential targets of these molecules. Here, we show that the enzymes responsible for the synthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG), diacylglycerol lipase alpha (DAGLα) and beta (DAGLβ), and degradation, monoacylglycerol lipase (MAGL), can be found in oligodendrocytes at different developmental stages. Moreover, cultured oligodendrocyte progenitor cells (OPCs) express DAGLα and β abundantly, resulting in the stronger production of 2-AG than in differentiated oligodendrocytes. The opposite is observed with MAGL. CB1 and CB2 receptor antagonists (SR141716 and AM630) impaired OPC differentiation into mature oligodendrocytes and likewise, inhibiting DAGL activity with RHC-80267 or tetrahydrolipstatin also blocked oligodendrocyte maturation, an effect reversed by the addition of exogenous 2-AG. Likewise, 2-AG synthesis disruption using specific siRNAs against DAGLα and DAGLβ significantly reduced myelin protein expression in vitro, whereas a pharmacological gain-of-function approach by using cannabinoid agonists or MAGL inhibition had the opposite effects. ERK/MAPK pathway is implicated in oligodendrocyte differentiation because PD98059, an inhibitor of MEK1, abrogated oligodendrocyte maturation. The cannabinoid receptor antagonists and RHC-80267 all diminished basal ERK1/2 phosphorylation, effects that were partially reversed by the addition of 2-AG. Overall, our data suggest a novel role of endocannabinoids in oligodendrocyte differentiation such that constitutive release of 2-AG activates cannabinoid receptors in an autocrine/paracrine way in OPCs, stimulating the ERK/MAPK signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878765     DOI: 10.1002/glia.21061

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  35 in total

1.  Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight.

Authors:  Vincenzo Di Marzo
Journal:  Nat Neurosci       Date:  2011-01       Impact factor: 24.884

Review 2.  Molecular model of cannabis sensitivity in developing neuronal circuits.

Authors:  Erik Keimpema; Ken Mackie; Tibor Harkany
Journal:  Trends Pharmacol Sci       Date:  2011-07-13       Impact factor: 14.819

3.  A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways.

Authors:  Oscar Gomez; Maria A Sanchez-Rodriguez; Silvia Ortega-Gutierrez; Henar Vazquez-Villa; Carmen Guaza; Francisco Molina-Holgado; Eduardo Molina-Holgado
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

Review 4.  Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells.

Authors:  Moises Garcia-Arencibia; Eduardo Molina-Holgado; Francisco Molina-Holgado
Journal:  Br J Pharmacol       Date:  2018-06-22       Impact factor: 8.739

Review 5.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

6.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

7.  Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.

Authors:  O Gomez; A Sanchez-Rodriguez; Mqu Le; C Sanchez-Caro; F Molina-Holgado; E Molina-Holgado
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

8.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

Review 9.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 10.  Endocannabinoid signaling and synaptic function.

Authors:  Pablo E Castillo; Thomas J Younts; Andrés E Chávez; Yuki Hashimotodani
Journal:  Neuron       Date:  2012-10-04       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.